Pharmacokinetics, Pharmacodynamics, and Safety of ET-26 in Subjects with Mild to Moderate Renal Impairment [0.03%]
ET-26在轻度至中度肾功能不全受试者中的药代动力学、药效学和安全性
Fan Yang,Chao-Zhuang Shen,Pan-Pan Ye et al.
Fan Yang et al.
Background and objectives: ET-26 is a novel etomidate analog with reduced adrenal suppression. This study evaluated its pharmacokinetics (PK), pharmacodynamics (PD), and safety in subjects with mild to moderate renal impa...
Omadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance [0.03%]
奥马达仙的药代动力学：特征、影响因素及临床意义
Huan Sun,Xiaoli Hou,Qiuzhen Zhu et al.
Huan Sun et al.
Omadacycline is a novel tetracycline with a wide range of antibacterial activity. A comprehensive understanding of the factors influencing its metabolic processes is essential to optimize its therapeutic benefits and minimize any potential ...
Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Omecamtiv Mecarbil in Healthy Chinese Subjects [0.03%]
一项多剂量递增研究，评估奥马西普在中国健康受试者中的安全性、耐受性和药代动力学特征
Xuening Li,Hui Li,Hongrong Xu et al.
Xuening Li et al.
Background and objectives: This phase I study was designed to evaluate the safety, tolerability, and pharmacokinetics of omecamtiv mecarbil with multiple oral doses at 25 mg twice daily, followed by titration to either 37...
Safety, Tolerability and Pharmacokinetics of a High-Dose, Rapid-Infusion Monoclonal Antibody: Phase I Results for Intravenous Sotrovimab 3000 mg [0.03%]
单次静脉注射高剂量（3000毫克）苏特科维姆аб的安全性、耐受性和药代动力学：I期临床研究结果
Yasmin Sánchez-Pearson,Jennifer Moore,Jerzy Daniluk et al.
Yasmin Sánchez-Pearson et al.
Background and objectives: The emergence of severe acute respiratory syndrome coronavirus 2 variants against which sotrovimab has lower in vitro neutralisation activity has led to the exploration of higher (> 500-mg intra...
Safety, Tolerability, Pharmacokinetics, and Viral Pharmacodynamics of the Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection in Participants with Early, Mild-to-Moderate COVID-19: A Randomized Clinical Trial [0.03%]
轻至中度新冠肺炎患者的早期肌肉注射单克隆抗体索托维单抗的安全性、耐受性、药代动力学和病毒药理动力学：一项随机临床试验
Anil Gupta,Maria Teresa Perez-Rodríguez,Yaneicy Gonzalez-Rojas et al.
Anil Gupta et al.
Background and objectives: New coronavirus disease 2019 (COVID-19) therapeutics, including intramuscular (IM) formulations, may increase patient access. In COMET-TAIL, sotrovimab 500 mg IM was non-inferior to 500 mg intra...
Bioequivalence of Two Perampanel Oral Suspension Formulations in Healthy Subjects: A Randomized Crossover Study [0.03%]
布南色林两种口服混悬液剂型在健康受试者中的生物等效性：一项随机交叉试验
Aya M AbdelMagid,Kamal A Badr,Mamdouh R Rezk
Aya M AbdelMagid
Background and objective: Perampanel has been approved for the adjunctive treatment of partial-onset seizures and primary generalized tonic-clonic seizures. The oral suspension formulation benefits patients who have diffi...
Efficacy and Safety of Ulinastatin in Post-traumatic Sepsis: A Randomized Controlled Trial [0.03%]
乌司他丁治疗创伤后脓毒症疗效与安全性的随机对照研究
Ao Yang,Rui Liu,Kongbo Lv et al.
Ao Yang et al.
Background and objective: Post-traumatic sepsis is associated with high mortality and limited treatment options. This study aimed to evaluate the safety and efficacy of ulinastatin in adult patients with post-traumatic se...
Bioequivalence Study of Bedaquiline and Sirturo® in Healthy Chinese Subjects Under Fasting and Postprandial Conditions: A Randomized, Open-Label, Single-Dose, Crossover Trial [0.03%]
贝达喹啉与市售药物Sirturo在空腹及餐后健康中国受试者中的生物等效性研究：一项随机、开放、单剂量、交叉试验
Yixuan Li,Yi Wu,Shufan Cai et al.
Yixuan Li et al.
Background and objective: Multidrug-resistant tuberculosis remains a major global health challenge, and bedaquiline has become an essential drug for its treatment. However, the high cost of the originator product Sirturo...
Establishment of a Vancomycin Population Pharmacokinetic Model for Pediatric Patients Based on the Non-Linear Mixed-Effects Model [0.03%]
基于非线性混合效应模型的儿童万古霉素群体药代动力学模型建立
Biao Yu,Kangkang Mei,Didi Zhan et al.
Biao Yu et al.
Background and objectives: Vancomycin (VCM) pharmacokinetic parameters vary widely between individuals. Existing models developed domestically and internationally may not apply universally because of differences in patien...